What is HC Wainwright's Estimate for NRXP Q3 Earnings?

Key Points

• Research analysts from HC Wainwright have projected NRx Pharmaceuticals will report a Q3 2025 earnings per share of ($0.08), maintaining a "Buy" rating with a price target of $40.00 for the stock.
• Several brokerages have reaffirmed their positive outlook on NRx Pharmaceuticals, with a consensus rating of "Buy" and an average target price of $34.50.
• NRx Pharmaceuticals' stock price opened at $3.15 after experiencing a significant trading increase of 10.9% recently.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) - Research analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of NRx Pharmaceuticals in a research note issued on Monday, September 8th. HC Wainwright analyst P. Trucchio anticipates that the company will earn ($0.08) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for NRx Pharmaceuticals' current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals' Q4 2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.11 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.11 EPS, FY2027 earnings at $2.53 EPS, FY2028 earnings at $5.00 EPS and FY2029 earnings at $5.49 EPS.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last released its earnings results on Monday, August 18th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.67).

A number of other equities research analysts have also weighed in on the stock. Zacks Research upgraded shares of NRx Pharmaceuticals to a "hold" rating in a report on Wednesday, September 10th. D. Boral Capital restated a "buy" rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a report on Monday, September 8th. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, BTIG Research restated a "buy" rating on shares of NRx Pharmaceuticals in a report on Monday, August 25th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $34.50.

NRx Pharmaceuticals Stock Up 1.1%

NRx Pharmaceuticals stock traded up $0.03 during mid-day trading on Wednesday, reaching $2.83. 184,325 shares of the company's stock were exchanged, compared to its average volume of 504,094. NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $6.01. The company has a fifty day moving average of $2.79 and a 200-day moving average of $2.56. The company has a market cap of $56.06 million, a P/E ratio of -1.26 and a beta of 1.63.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of institutional investors have recently bought and sold shares of NRXP. Squarepoint Ops LLC purchased a new stake in NRx Pharmaceuticals in the fourth quarter valued at approximately $56,000. Millennium Management LLC purchased a new stake in NRx Pharmaceuticals in the fourth quarter valued at approximately $61,000. Geode Capital Management LLC grew its holdings in NRx Pharmaceuticals by 27.9% in the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company's stock valued at $562,000 after purchasing an additional 37,598 shares during the period. Finally, Anson Funds Management LP grew its holdings in NRx Pharmaceuticals by 535.1% in the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company's stock valued at $2,417,000 after purchasing an additional 993,401 shares during the period. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.